« Back
Home /
CA 15-3 ELISA

CA 15-3 ELISA

Manufacturer	Calbiotech
Category	Oncology By Cell Type Carcinoma Hematology Myeloma Cell Biology Cell Status ELISA Autophagy ELISA & Immunoassays ELISA Kits Immunoassay By Organ Breast Cancer Testicular & Prostate Cancer
Type	Elisa-Kit
Specific against	other
Amount	96T
Item no.	CA240T
Targets	CD227
eClass 6.1	32160605
eClass 9.0	32160605
Available
Sensitivity	15 U/mL
Runtime	60/60/15 mins
References	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5022658/
Certification	CE Mark
References	Aziz DC, Peter JB. DNA ploidy and cell-cycle analysis. Tools for assessment of cancer prognosis. J Clin Pathol 1991; 5:422-38. Clark GM, Dressler LG, Owens MA, Dounds G, Oldaker T, McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989; 320:627-33. Elledge RM, McGuire WL. Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. Annu Rev Med 1993; 44:201-10. Foekens JA, Rio C, Seguin P, et al. Prediction of relapse and survival in breast cancer patients by pS2 protein. Cancer Res 1990; 50-3832-7. Isola J, Visakorp T, Holli K, Kallionieml D. Association of p53 expression with other prognostic factors and long term survival in node-negative breast cancer. J Cell Biochem 1992; (Suppl 16D):101. Kute TE, Shao ZM, Snugg NK, Long RT, Russell GB, Case LD. Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 1992; 52-198-203. McGuire WL, Tandon AK, Allred D, Chamnes GC, Clark GM. How to use prognostic factors in axillary node negative breast cancer patients. J Natl Cancer Inst 1990; 82:1006-7. Nicholson S, Richard J, Sainsbury C, et al. Epidermal growth factor receptor (EGFr): results of a 6 year follow up study in operable breast cancer with emphasis on the node-negative subgroup. Br J Cancer 1991; 63:146-50. Somerville JE, Clarke LA, Biggart JD. C-erb B-2 overexpression and histological type of in-situ and invasive breast carcinoma. J Clin Pathol 1992; 45-16-20.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

CA240T-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 96T

available

Delivery expected until 5/9/2024